CCK8 and transwell assays suggested that IGF2BP3 promoted RCC proliferation and metastasis through CD44 and HMGA2 (Figures 6A,B and S15A,B), which was consistent with published studies. The gene discussed is IGF2BP3; the disease is renal cell carcinoma.